Precision BioSciences (DTIL) announced that it will be issued U.S. Patent No. 12,410,418 by the U.S. Patent and Trademark Office on September 9. The composition of matter claims in this U.S. patent will encompass the PBGENE-HBV ARCUS nuclease utilized in the company’s lead in vivo gene editing program, which recognizes a highly conserved target sequence present in both HBV covalently closed circular DNA and integrated HBV DNA. This U.S. patent will have an expiration date in March 2042. The company was granted patents in Europe and Hong Kong earlier this year with similar composition of matter claims.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DTIL:
- Precision BioSciences Updates Executive Employment Agreements
- Precision BioSciences: Promising Clinical Milestones and Strategic Advancements Drive Buy Rating
- Precision BioSciences Reports Significant Quarterly Loss
- Positive Outlook for Precision BioSciences Amid Promising Clinical Trial Data and Strategic Advancements
- Promising Phase 1 Data and Strong Financial Position Justify Buy Rating for Precision BioSciences’ PBGENE-HBV